Supplementary Table S1. Pre-treating PBMC with IL-2 did not affect ADCC induced by avelumab of the human lung carcinoma cell line H441

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  | E:T ratio |  |
| Pre-treatment | Avelumab | 100:1 | 50:1 | 25:1 |
| IL-2 (200 U/ml) | 10 µg/ml | 47.4 (1.7) | 42.8 (3.0) | 31.4 (1.8) |
|  | 5 µg/ml | 44.3 (1.3) | 40.1 (1.9) | 28.8 (0.3) |
|  | Isotype 10 µg/ml | 9.9 (0.5) | 4.6 (1.0) | 7.5 (1.2) |
| None | 10 µg/ml | 46.4 (2.6) | 29.4 (7.7) | 19.4 (0.9) |
|  | 5 µg/ml | 49.6 (2.4) | 32.6 (3.0) | 20.0 (1.9) |
|  | Isotype 10 µg/ml | 6.0 (1.8) | 7.2 (1.0) | -0.7 (0.8) |

ADCC assay of the human lung carcinoma cell line H441 using as effectors PBMC from one healthy donor. The PBMC were either rested overnight or treated with 200 U/ml of rhIL-2 overnight. Data shown is the mean (SD) % target cell lysis of triplicate wells determined by an 111In-release assay as described in Materials and Methods, at 2 concentrations of avelumab, and with 3 different effector cell : target cell (E:T) ratios.

Supplementary Table S2. Pre-treating purified NK cells with IL-12 did not increase ADCC activity mediated by avelumab of the human carcinoma cell lines HT29 and ASPC-1 more than the isotype control

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  | Avelumab |  | Isotype |
| Tumor cell line | Treatment | 0.02 µg/ml | 0.002 µg/ml | 0.0002 µg/ml | 0.0002 µg/ml |
| HT29 | 0 | 6.2 (1.4) | 4.6 (0.03) | 3.3 (1.4) | 3.3 (0.5) |
|  | IL-12  | 19.5 (0.9) | 18.9 (1.5) | 16.9 (0.2) | 13.8 (3.2) |
| ASPC-1 | 0 | -1.3 (1.2) | -0.3 (0.5) | 0.5 (1.1) | -0.2 (1.4) |
|  | IL-12  | 10.1 (3.0) | 11.2 (1.8) | 9.3 (1.7) | 11.7 (2.3) |

ADCC assay of the human colon carcinoma cell line HT29 and the human pancreatic carcinoma cell line ASPC-1 using as effectors purified NK cells from one healthy donor. The NK cells were either rested overnight or treated with 10 ng/ml of rhIL-12 overnight. Data shown is the mean (SD) % target cell lysis of triplicate wells determined by an 111In-release assay as described in Materials and Methods, at 3 concentrations of avelumab, and an effector cell : target cell (E:T) ratio of 20:1. Isotype control antibody was used at 0.0002 µg/ml.